Physician profile
Alan Schonfeld
NPI 1174638886
$1,664.37
in general payments reported to CMS, 2019-2025
25 companies · $681 in 2025
The $681 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.64 · 2023: $355 · 2024: $616 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $372.01 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $261.60 | 2023-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $141.50 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.32 | 2025 | Caplyta |
| Pfizer INC. | $96.18 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $74.11 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.87 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $69.52 | 2025 | Ozempic, Rybelsus |
| Abbvie INC. | $62.30 | 2023-2025 | Vraylar |
| Astellas Pharma US INC | $56.73 | 2023-2025 | Veozah |
| Lundbeck LLC | $45.45 | 2025 | Rexulti |
| Abiomed | $38.62 | 2025 | |
| Sk Life Science, INC. | $36.70 | 2024-2025 | |
| Exact Sciences Corporation | $31.26 | 2024-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $31.06 | 2024 | Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $25.56 | 2023 | |
| Alk-Abello, INC | $21.40 | 2024 | Grastek, Odactra, Ragwitek |
| Indivior INC. | $19.93 | 2024 | Perseris |
| Abbott Laboratories | $19.85 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $17.46 | 2024 | Repatha |
| Phathom Pharmaceuticals, INC. | $15.23 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $14.31 | 2023 | Xarelto |
| Vanda Pharmaceuticals INC. | $13.57 | 2024 | Fanapt, Hetlioz |
| Lilly USA, LLC | $13.19 | 2023 | Mounjaro |
| Tactile Systems Technology INC | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Schonfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.